Latest Biotech News

Novartis agreed to pay $1.1 billion upfront to acquire UK biotech Myricx Bio, adding an antibody-drug conjugate (ADC) payload platform designed to address limitations seen with existing...

United Therapeutics agreed to buy Thymmune Therapeutics in a $300 million regenerative medicine transaction aimed at restoring T-cell function using thymic cell therapies derived from iPSCs. The...

Celea Therapeutics secured $180 million to support a Phase 3 pivotal study for deupirfenidone, an oral small-molecule candidate for idiopathic pulmonary fibrosis (IPF). PureTech Health’s spinout...

Abivax shares jumped after newly reported ABTECT Maintenance Part 2 results for obefazimod in adults with moderately to severely active ulcerative colitis. In the supplemental portion, 37.2% of...

Cancer- and immune-focused drug developers are dominating early-stage venture capital funding so far in 2026, accounting for more than 40% of both the number of biotech companies and total capital...

CMS published a proposed 2027 outpatient payment rule that includes a 2.4% base rate increase while imposing steep cuts to 340B drug payments and expanding site-neutral payment to off-campus...

KFF estimates Medicare will spend about $13.4 billion on the Medicare Advantage Quality Bonus Program in 2026, a level set against ongoing scrutiny of the program. The Quality Bonus Program...

GOP lawmakers urged the Trump-era FDA/HHS apparatus to ensure clinical trials enroll diverse participants, reframing the policy as aligning trial populations with intended patients rather than...

Evercore ISI downgraded Twist Bioscience shares to “In Line” from “Outperform,” citing that near-term expectations appear ahead of fundamentals. The analyst, Vijar Kumar, pointed to the stock’s...

A review of the largest biotech funding rounds in June 2026 highlighted Parabilis Medicines, NewLimit, Enliven Therapeutics, and Kardigan as the top capital-raising stories across the month. The...

A STAT+ report says GOP lawmakers are pushing the Trump administration to ensure clinical trials are more diverse, arguing that the issue is about enrolling trial populations that better reflect...

Novartis agreed to pay $1.1 billion upfront to acquire Myricx Bio, aiming to expand its antibody-drug conjugate (ADC) pipeline with a payload platform built around N-myristoyltransferase inhibitor...

Celea Therapeutics, a PureTech Health spinout focused on respiratory disease, secured $180 million to fund a pivotal Phase 3 study of deupirfenidone for idiopathic pulmonary fibrosis (IPF). The...

Abivax shares climbed sharply after updated data from its Phase 3 ulcerative colitis (UC) program, helping the company’s stock rebound following earlier safety-related volatility around...

Anthropic CEO Dario Amodei told STAT+ that AI’s “decade’s worth of progress per year” vision for biotech and pharma may not arrive on the originally expected timeline. At an Anthropic event...

A new report examines whether AI can improve the odds of a successful IVF pregnancy by focusing on how some fertility clinics are using AI for sperm and embryo selection. The piece highlights the...

A team reported Phase Ib results for a personalized neoantigen dendritic cell vaccine in newly diagnosed glioblastoma, with findings published in Nature Communications. The approach uses...

Research described in a new report says Natural Language Processing (NLP) tools outperform ICD-10 coding for capturing clinically relevant information, a finding aimed at improving the fidelity of...

Nature Biotechnology published a piece arguing that hybrid quantum–classical computers could achieve “quantum advantage” in biotechnology before fully capable quantum machines are available. The...

Researchers reported new molecular insights into C5aR2, a complement receptor that signals in ways that depart from classical expectations, adding clarity to how the complement pathway regulates...